TNF blockade in the treatment of rheumatoid arthritis: Infliximab versus etanercept

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 1, 2001, Pages 75-84

  Mikuls, T R ^a   Moreland, L W ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Etanercept; Infliximab; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; ETANERCEPT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; INFLIXIMAB; METHOTREXATE; PLACEBO; PROTEIN P75; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIBODY PRODUCTION; ANTIGENICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEADACHE; HUMAN; INJECTION SITE; LONG TERM CARE; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; IMMUNOGLOBULIN G; MICE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035003994     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.1.75     Document Type: Review

References (45)

1. Early rheumatoid arthritis: Time to aim for remission?
2. Severe functional declines, work disability and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years
3. The lifetime costs of rheumatoid arthritis
4. The changing face of rheumatoid arthritis therapy: Results of serial surveys
5. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A meta-analysis of published clinical trials
6. Long-term therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone
7. Tumor necrosis factor
8. Coley toxins - The first century
9. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
10. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum
11. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
12. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
13. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on Type II collagen-induced arthritis in mice
14. Cytokines in autoimmunity
15. Soluble tumor necrosis receptors in human inflammatory synovial fluids
16. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy
17. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial and endothelial cells
18. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage
19. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
20. The dimensions of health outcomes: The health assessment questionnaire, disability and pain scores
21. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-alpha (cA2) versus placebo in rheumatoid arthritis
22. Repeated therapy with monoclonal antibody to tumor necrosis factor-alpha (cA2) in patients with rheumatoid arthritis
23. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in the treatment of rheumatoid arthritis
24. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment in patients with rheumatoid arthritis receiving methotrexate therapy
25. Infliximab (chimeric anti-tumor necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised Phase III trial
26. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs, based on the findings in patients treated with placebo
27. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis
28. 54-week clinical and radiographic results from the ATTRACT trial: A Phase III study of infliximab (Remicade) in patients with active RA despite methotrexate
29. Recombinant soluble TNF receptor (p80) fusion protein: Toxicity and dose finding trial in refractory RA
30. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
31. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial
32. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
33. A Phase III trial of etanercept vs. methotrexate (MTX) in early rheumatoid arthritis
34. Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis
35. Long-term safety and efficacy of combination therapy with methotrexate (MTX) and etanercept (Enbrel®)
36. Clinical and pharmacological experience with etanercept
37. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis
38. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions
39. 2E7 in rheumatoid arthritis
40. 2E7 slows radiographic disease progression in rheumatoid arthritis
41. Non-immunogenicity of a pegylated soluble tumor necrosis factor receptor Type I (PEG sTNF-RI [p55])
42. Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: A novel mechanism of activation of synoviocytes
43. Rheumatoid arthritis: Anticytokine therapies on the horizon